Journal
INFLAMMATORY BOWEL DISEASES
Volume 26, Issue 7, Pages E62-E63Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/ibd/izaa092
Keywords
double biologic therapy (DBT); vedolizumab; ustekinumab; stricture; Crohn's disease
Categories
Funding
- National Institutes of Health of CCTS funding [TL1TR001997]
- National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [R21DK118954]
- United States Department of Veterans Affairs Laboratory Research and Development Program [I01CX001353]
Ask authors/readers for more resources
Stricturing Crohn's disease (CD) is a severe phenotype that presents unique challenges to therapeutic management. Emerging literature suggests that anti-TNF monoclonal antibody (mAb) therapies are inadequate for preventing progression to stricture. We hereby present a case of a patient with refractory CD who required multiple surgical resections despite several anti-TNF treatment regimens. Subsequent surgical complications were avoided after changing to combination vedolizumab and ustekinumab therapies every 4 weeks. This case argues for a tailored approach to CD therapy based on disease phenotype and demonstrates that combination therapy with ustekinumab and vedolizumab is a viable option for patients with stricturing disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available